Biggest News Aggregation in the World
๐Ÿ“ฐ Thyroid Nodules News

Page 2 - Thyroid Nodules News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Thyroid Nodules. Real-time updates on events, politics, business and more.

The LUCA device shows high accuracy in thyroid cancer screening

The LUCA device shows high accuracy in thyroid cancer screening Thyroid nodules are a common pathology having a prevalence of 19-76% when screened with ultrasound, with higher frequencies in women. Current medical methods used to assess the malignancy of a nodule consist in performing an ultrasound, followed by a Doppler ultrasound, and then a biopsy. However, unfortunately, these methods present both low specificity and low sensitivity. This insufficient effectiveness in accurately being able ...
Comunidad Autonoma De Cataluna Turgut Durduran Ramon Gomis Mireia Mora Emily Henderson Pii Sunyer Biomedical Research Institute

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News โ†’

The LUCA device proves its readiness for a better thyroid cancer screening

ย E-Mail IMAGE:ย First lab tests in 2019 of the LUCA device at ICFO research center in Barcelona. Dr. Mattia Squarcia tests the probe on a healthy patient to see the performance of... view moreย  Credit: ICFO Thyroid nodules are a common pathology having a prevalence of 19-76% when screened with ultrasound, with higher frequencies in women. Current medical methods used to assess the malignancy of a nodule consist in performing an ultrasound, followed by a Doppler ultrasound, and then a b...
United Kingdom Comunidad Autonoma De Cataluna Turgut Durduran Lorenzo Cortese Ramon Gomis Feliciaa Hanzu

Exelixis Announces Cabozantinib Significantly Improved Progression-Free Survival in COSMIC-311 Phase 3 Pivotal Trial in Patients with Previously Treated Radioiodine-Refractory Differentiated Thyroid Cancer

Published: Dec 21, 2020 ALAMEDA, Calif.--(BUSINESS WIRE)-- Exelixis, Inc. (NASDAQ: EXEL) today announced that COSMIC-311, the phase 3 pivotal trial evaluating cabozantinib (CABOMETYX ยฎ) versus placebo in patients with radioiodine-refractory differentiated thyroid cancer who have progressed after up to two prior vascular endothelial growth factor receptor (VEGFR)-targeted therapies, met the co-primary endpoint of demonstrating significant improvement in progression-free survival. Cabozantin...
United States Marcias Brose Gisela Schwab Abramson Cancer Center Takeda Pharmaceutical Company American Thyroid Association

Detailed text transcripts for TV channel - FOXNEWS - 20120916:14:34:00

Do that? >> it is point for doctors to be involved, if your doctors thinks so -- and the dha an epa, that is what is in fish and know the good stuff is in the fatty fish we are talking about and the salmon and mackerel and the sardines, you get the good stuff there. >> jamie: always better in food. >> if possible. >> eric: especially it is grilled. and, people diagnosed with thyroid disease, they say 27 million americans have thyroid disease, and, 13 million are undiagnosed. dr. samadi, how do y...
Dha An Epa Thyroid Disease 27 Million Smood Samadi 13 Million Thyroid Nodules

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science